Oppenheimer Holdings, Inc. set a $3.00 price target on BioLineRx Ltd. (NASDAQ:BLRX) in a report issued on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also recently commented on BLRX. ValuEngine upgraded BioLineRx from a sell rating to a hold rating in a research note on Monday, July 17th. Roth Capital started coverage on BioLineRx in a research note on Thursday, August 3rd. They issued a buy rating and a $3.00 price target on the stock. Zacks Investment Research upgraded BioLineRx from a sell rating to a hold rating in a research note on Thursday, September 7th. Finally, Maxim Group set a $3.00 price target on BioLineRx and gave the stock a buy rating in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $2.88.

Shares of BioLineRx (BLRX) traded up 0.44% during midday trading on Wednesday, reaching $1.14. The company’s stock had a trading volume of 311,303 shares. The firm’s 50 day moving average is $1.13 and its 200 day moving average is $0.97. BioLineRx has a 52 week low of $0.80 and a 52 week high of $1.38. The firm’s market capitalization is $109.00 million.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.05). Equities analysts forecast that BioLineRx will post ($0.24) EPS for the current fiscal year.

WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/biolinerx-ltd-blrx-given-a-3-00-price-target-at-oppenheimer-holdings-inc/1641667.html.

Large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC lifted its stake in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 86,481 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of BioLineRx in the first quarter worth about $126,000. Finally, KCG Holdings Inc. lifted its stake in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 153,687 shares in the last quarter. Institutional investors and hedge funds own 32.27% of the company’s stock.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.